Approach to atherosclerotic renovascular disease: 2016

Reem Daloul1, Aubrey R Morrison1

  • 1Renal Division, Department of Internal Medicine , Washington University School of Medicine , 660 South Euclid, Box 8126, St Louis, MO 63110 , USA.

Clinical Kidney Journal
|September 29, 2016
PubMed

Insights

Optimal medical management is recommended over endovascular intervention for atherosclerotic renal artery stenosis, based on current clinical trial evidence. This review discusses trial limitations and offers guidance for managing these complex patients.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Interventional Cardiology

Background:

  • Atherosclerotic renal artery stenosis (ARAS) presents a management challenge, particularly in hypertensive patients or those with renal impairment.
  • Current guidelines, influenced by major trials like the Angioplasty and Stenting for Renal Atherosclerotic Lesions (ASIL) and Cardiovascular Outcomes for Renal Artery Lesions (CORAL) trials, favor optimal medical management over revascularization.
  • The dilemma persists regarding the optimal treatment strategy for ARAS.

Purpose of the Study:

  • To critically evaluate the limitations and implications of contemporary clinical trials on ARAS management.
  • To present a structured approach for managing patients with ARAS.
  • To formulate clear recommendations for the clinical practice of ARAS treatment.

Main Methods:

  • Review and critical analysis of existing clinical trial data (ASIL, CORAL).
  • Discussion of the limitations inherent in current research methodologies for ARAS.
  • Synthesis of evidence to propose a practical management strategy.

Main Results:

  • Major clinical trials suggest endovascular intervention offers limited benefit over optimal medical management for most ARAS patients.
  • Limitations in trial design and patient selection may impact the generalizability of findings.
  • Optimal medical management remains the cornerstone of ARAS care.

Conclusions:

  • Endovascular intervention for ARAS should be carefully considered, with a strong emphasis on optimal medical therapy.
  • Further research is needed to identify patient subgroups who may benefit from revascularization.
  • Clearer guidelines and individualized treatment plans are essential for managing ARAS effectively.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
553
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
530
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
359
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.8K